Epify is focused on benefiting patients, doctors, payers and partners, both academic and industrial, to drive biomarkers into clinical practice and improve the diagnosis and treatment of cancer patients.

Epify is focused on benefiting patients, doctors, payers and partners, both academic and industrial, to drive biomarkers into clinical practice and improve the diagnosis and treatment of cancer patients.

LICENSING

Epify licenses biomarker discovery IP and shares revenue with its licensees from the commercialization of these biomarkers as diagnostic tests. Industrial partners may also license Epify’s biomarkers to use in their diagnostic tests or as a basis for developing their own tests.

VALIDATION

Many biomarkers that are discovered de novo and described in literature require validation in independent patient cohorts in order to prove their scientific validity. Epify collaborates with its medical and academic partners, together with patient associations, to develop and execute these validation studies.

CLINICAL UTILITY

The utility of a specific biomarker test in clinical practice hinges on its ability to influence the clinician’s decision, allowing them to select the most appropriate treatment and provide the most clarity to patients about the potential course of their disease. Epify develops these clinical utilities in close collaboration with doctors, payers and patients, executing the necessary studies to demonstrate that the biomarker test results can be used to support clinical decision making.

SERVICES

Together with academic collaborators, Epify provides test development services, designing and executing validation or utility studies from its own laboratories.